

**ENVIRONMENTAL PROTECTION AGENCY****[FRL-10001-22-OAR]****Acid Rain Program: Excess Emissions Penalty Inflation Adjustments****AGENCY:** Environmental Protection Agency (EPA).**ACTION:** Notice of annual adjustment factors.

**SUMMARY:** The Acid Rain Program requires sources that do not meet their annual Acid Rain emissions limitations for sulfur dioxide (SO<sub>2</sub>) or nitrogen oxides (NO<sub>x</sub>) to pay inflation-adjusted excess emissions penalties. This document provides notice of the annual adjustment factors used to calculate excess emissions penalties for compliance years 2019 and 2020.

**FOR FURTHER INFORMATION CONTACT:** Jason Kuhns at (202) 564-3236 or [kuhns.jason@epa.gov](mailto:kuhns.jason@epa.gov).

**SUPPLEMENTARY INFORMATION:** The Acid Rain Program limits SO<sub>2</sub> and NO<sub>x</sub> emissions from fossil fuel-fired electricity generating units. All affected sources must hold allowances sufficient to cover their annual SO<sub>2</sub> mass emissions, and certain coal-fired units must meet annual average NO<sub>x</sub> emission rate limits. Under 40 CFR 77.6, any source that does not meet these requirements must pay an excess emissions penalty without demand to the EPA Administrator. The automatic penalty is computed as the number of excess tons of SO<sub>2</sub> or NO<sub>x</sub> emitted times a per-ton penalty amount of \$2,000 times an annual adjustment factor, which must be published in the **Federal Register**.

The annual adjustment factor used to compute excess emissions penalties for compliance year 2019 is 2.0236, resulting in an automatic penalty amount of \$4,047 per excess ton of SO<sub>2</sub> or NO<sub>x</sub> emitted in 2019. In accordance with 40 CFR 77.6(b) and 72.2, this annual adjustment factor is determined from values of the Consumer Price Index for All Urban Consumers (CPI-U) for August 1989 and August 2018.

The annual adjustment factor used to compute excess emissions penalties for compliance year 2020 is 2.0591, resulting in an automatic penalty amount of \$4,118 per excess ton of SO<sub>2</sub> or NO<sub>x</sub> emitted in 2020. This annual adjustment factor is determined from values of the CPI-U for August 1989 and August 2019.

Dated: September 25, 2019.

**Reid P. Harvey,**

*Director, Clean Air Markets Division, Office of Atmospheric Programs, Office of Air and Radiation.*

[FR Doc. 2019-22696 Filed 10-16-19; 8:45 am]

**BILLING CODE 6560-50-P****FEDERAL DEPOSIT INSURANCE CORPORATION****Sunshine Act Meetings**

**TIME AND DATE:** Pursuant to the provisions of the "Government in the Sunshine Act" (5 U.S.C. 552b), notice is hereby given that at 10:43 p.m. on Tuesday, October 15, 2019, the Board of Directors of the Federal Deposit Insurance Corporation met in closed session to consider matters related to the Corporation's supervision, corporate, and resolution activities.

**PLACE:** The meeting was held in the Board Room located on the sixth floor of the FDIC Building located at 550 17th Street NW, Washington, DC.

**STATUS:** The meeting was closed to the public.

**MATTERS TO BE CONSIDERED:** In calling the meeting, the Board determined, on motion of Director Martin J. Gruenberg, seconded by Kathleen L. Kraninger (Director, Consumer Financial Protection Bureau), and concurred in by Director Joseph M. Otting (Comptroller of the Currency) and Chairman Jelena McWilliams, that Corporation business required its consideration of the matters which were to be the subject of this meeting on less than seven days' notice to the public; that no earlier notice of the meeting was practicable; that the public interest did not require consideration of the matters in a meeting open to public observation; and that the matters could be considered in a closed meeting by authority of subsections (c)(4), (c)(6), (c)(8), (c)(9)(A)(ii), and (c)(9)(B) of the "Government in the Sunshine Act" (5 U.S.C. 552b(c)(4), (c)(6), (c)(8), (c)(9)(A)(ii), and (c)(9)(B)).

**CONTACT PERSON FOR MORE INFORMATION:** Requests for further information concerning the meeting may be directed to Robert E. Feldman, Executive Secretary of the Corporation, at 202-898-7043.

Dated at Washington, DC, on October 15, 2019.

Federal Deposit Insurance Corporation.

**Robert E. Feldman,***Executive Secretary.*

[FR Doc. 2019-22775 Filed 10-15-19; 4:15 pm]

**BILLING CODE 6714-01-P****FEDERAL ELECTION COMMISSION****Sunshine Act Meetings**

**TIME AND DATE:** Tuesday, October 22, 2019 at 10:00 a.m.

**PLACE:** 1050 First Street NE, Washington, DC.

**STATUS:** This meeting will be closed to the public.

**MATTERS TO BE CONSIDERED:** Matters concerning participation in civil actions or proceedings or arbitration.

**CONTACT PERSON FOR MORE INFORMATION:** Judith Ingram, Press Officer, Telephone: (202) 694-1220.

**Vicktoria J. Allen,***Acting Deputy Secretary of the Commission.*

[FR Doc. 2019-22811 Filed 10-15-19; 4:15 pm]

**BILLING CODE 6715-01-P****DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration****[Docket No. FDA-2018-N-3263]****Request for Nominations for Voting Members on the Tobacco Products Scientific Advisory Committee**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is requesting nominations for members to serve on the Tobacco Products Scientific Advisory Committee, in the Center for Tobacco Products. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore, encourages nominations of appropriately qualified candidates from these groups.

**DATES:** Nominations received on or before December 16, 2019 will be given first consideration for membership on the Tobacco Products Scientific Advisory Committee. Nominations received after December 16, 2019 will be considered for nomination to the committee as later vacancies occur.

**ADDRESSES:** All nominations for membership should be sent electronically by logging into the FDA Advisory Nomination Portal: <https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm>, or by mail to Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993-0002.

**FOR FURTHER INFORMATION CONTACT:**

Regarding all nomination questions for membership, the primary contact is: Janice O'Connor, Office of Science, Center for Tobacco Products, Food and Drug Administration, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G335, Silver Spring, MD 20993-0002, 1-877-287-1373 (choose Option 5), email: [TPSAC@fda.hhs.gov](mailto:TPSAC@fda.hhs.gov).

Information about becoming a member on an FDA advisory committee can also be obtained by visiting FDA's website at: <http://www.fda.gov/AdvisoryCommittees/default.htm>.

**SUPPLEMENTARY INFORMATION:** FDA is requesting nomination for voting members on the Tobacco Products Scientific Advisory Committee.

**I. General Description of the Committee Duties**

The Tobacco Products Scientific Advisory Committee advises the Commissioner of Food and Drugs (the Commissioner) or designee in discharging responsibilities related to the regulation of tobacco products. The committee reviews and evaluates safety, dependence, or health issues relating to tobacco products and provides appropriate advice, information, and recommendations to the Commissioner.

**II. Criteria for Voting Members**

The committee consists of 12 members including the Chair. Members and the Chair are selected by the Commissioner or designee from among individuals knowledgeable in the fields of medicine, medical ethics, science, or technology involving the manufacture, evaluation, or use of tobacco products. Almost all non-Federal members of this committee serve as Special Government Employees. The committee includes nine technically qualified voting members, selected by the Commissioner or designee. The nine voting members include seven members who are physicians, dentists, scientists, or healthcare professionals practicing in the areas of oncology, pulmonology, cardiology, toxicology, pharmacology, addiction, or any other relevant specialty. The nine voting members also include one member who is an officer or employee of a State or local government or of the Federal Government, and one member who is a representative of the general public. Members will be invited to serve for terms of up to 4 years.

**III. Nomination Procedures**

Any interested person may nominate one or more qualified individuals for membership on the advisory committee. Self-nominations are also accepted.

Nominations must include a current, complete résumé or curriculum vitae for each nominee, including current business address and/or home address, telephone number, and email address if available. Nominations must also specify the advisory committee for which the nominee is recommended. Nominations must also acknowledge that the nominee is aware of the nomination unless self-nominated. FDA will ask potential candidates to provide detailed information concerning such matters related to financial holdings, employment, and research grants and/or contracts to permit evaluation of possible sources of conflicts of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: October 10, 2019.

**Lowell J. Schiller,**

*Principal Associate Commissioner for Policy.*

[FR Doc. 2019-22685 Filed 10-16-19; 8:45 am]

**BILLING CODE 4164-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration**

[Docket No. FDA-2018-N-3263]

**Request for Nominations of a Nonvoting Representative of the Interest of the Tobacco Manufacturing Industry on the Tobacco Products Scientific Advisory Committee**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is requesting nominations for a nonvoting representative of the interests of the tobacco manufacturing industry to serve on the Tobacco Products Scientific Advisory Committee (TPSAC), in the Center for Tobacco Products. FDA seeks to include the views of women and men, members of all racial and ethnic groups, and individuals with and without disabilities on its advisory committees and, therefore encourages nominations of appropriately qualified candidates from these groups. A nominee may either be self-nominated or nominated by an organization.

In addition, FDA is requesting that any industry organizations interested in participating in the selection of a nonvoting representative of the interests of the tobacco manufacturing industry to serve on the TPSAC notify FDA in writing. Nominations will be accepted

for either the representative to serve on TPSAC or for the selection group effective with this notice.

**DATES:** Nomination materials for prospective candidates should be sent to FDA by November 18, 2019. Concurrently, any industry organization interested in participating in the selection of an appropriate nonvoting member to represent the interests of the tobacco manufacturing industry must send a letter stating that interest to FDA by November 18, 2019, (see sections I and II of this document for further details).

**ADDRESSES:** All nominations for nonvoting representatives of the interests of the tobacco manufacturing industry may be submitted electronically by accessing the FDA Advisory Committee Membership Nomination Portal at: <https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm>, or by mail to Advisory Committee Oversight and Management Staff, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993-0002.

All statements of interest from industry organizations interested in participating in the selection process of nonvoting representatives of the interests of the tobacco manufacturing industry nomination should be sent to Janice O'Connor (see **FOR FURTHER INFORMATION CONTACT**).

**FOR FURTHER INFORMATION CONTACT:** Janice O'Connor, Office of Science, Center for Tobacco Products, Food and Drug Administration, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G335, Silver Spring, MD 20993-0002, 1-877-287-1373 (choose Option 5), email: [TPSAC@fda.hhs.gov](mailto:TPSAC@fda.hhs.gov).

Information about becoming a member of an FDA advisory committee can also be obtained by visiting FDA's website at: <http://www.fda.gov/AdvisoryCommittees/default.htm>.

**SUPPLEMENTARY INFORMATION:** FDA is requesting nominations for a nonvoting representative of the interests of the tobacco manufacturing industry on the Tobacco Products Scientific Advisory Committee (TPSAC).

**I. General Description of the Committee Duties**

The TPSAC advises the Commissioner of Food and Drugs (the Commissioner) or designee in discharging responsibilities related to the regulation of tobacco products. The TPSAC reviews and evaluates safety, dependence, or health issues relating to tobacco products and provides